德孚在中国

9 7 0 5 2

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

使用还原敏感的脂质 - 聚合物杂合纳米颗粒进行多柔比星 (Doxorubicin) 和雷公藤 (triptolide) 内酯共同递送，用于体外和体内协同癌症治疗

 

Authors Wu B, Lu S, Zhang L, Zhuo RX, Xu HB, Huang SW

Received 28 December 2016

Accepted for publication 13 February 2017

Published 8 March 2017 Volume 2017:12 Pages 1853—1862

DOI https://doi.org/10.2147/IJN.S131235

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jiang Yang

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun

Abstract: Codelivery is a promising strategy to overcome the limitations of single chemotherapeutic agents in cancer treatment. Despite progress, codelivery of two or more different functional drugs to increase anticancer efficiency still remains a challenge. Here, reduction-sensitive lipid–polymer hybrid nanoparticles (LPNPs) drug delivery system composed of monomethoxy-poly(ethylene glycol)-S -S -hexadecyl (mPEG-S -S -C16), soybean lecithin, and poly(d,l-lactide-co-glycolide) (PLGA) was used for codelivery of doxorubicin (DOX) and a Chinese herb extract triptolide (TPL). Hydrophobic DOX and TPL could be successfully loaded in LPNPs by self-assembly. More importantly, drug release and cellular uptake experiments demonstrated that the two drugs were reduction sensitive, released simultaneously from LPNPs, and taken up effectively by the tumor cells. DOX/TPL-coloaded LPNPs (DOX/TPL-LPNPs) exhibited a high level of synergistic activation with low combination index (CI) in vitro and in vivo. Moreover, the highest synergistic therapeutic effect was achieved at the ratio of 1:0.2 DOX/TPL. Further experiments showed that TPL enhanced the uptake of DOX by human oral cavity squamous cell carcinoma cells (KB cells). Overall, DOX/TPL-coencapsulated reduction-sensitive nanoparticles will be a promising strategy for cancer treatment.
Keywords: triptolide, codelivery, reduction sensitive, synergistic effect


Download Article[PDF]